Free PKC catalytic subunits (PKM) phosphorylate tau via a pathway distinct from that utilized by intact PKC.
Protein kinase C (PKC) is reversibly activated at the plasma membrane by the generation of diacylglycerol (DAG) coupled with the release of Ca2+ from intracellular stores. PKC is also irreversibly activated by calpain-mediated PKC cleavage of the regulatory and catalytic subunits; resultant free PKC catalytic subunits are termed "PKM". Unlike PKC, PKM is co-factor-independent, remains active following diffusion away from the membrane, and can theoretically phosphorylate targets inaccessible to, and inappropriate for, PKC. We examined the downstream consequences of PKC activation by the phorbol ester TPA and by ionophore A23187-mediated calcium influx (which experimentally correspond to DAG-mediated and calpain-mediated activation, respectively) on phosphorylation of the microtubule-associated protein tau. Both methods increased phospho-tau immunoreactivity, and neither was inhibited by lithium or olomoucin (inhibitors of tau kinases GSK-3 beta and cdk5, respectively). The TPA-mediated increase, and not the ionophore-mediated increase, was blocked by co-treatment with the mitogen-activated protein (MAP) kinase kinase inhibitor PD98059. These findings indicate that PKC phosphorylates tau via the MAP kinase pathway, but that PKM can bypass this requirement, therefore demonstrating that distinct intracellular pathways can be mediated by PKC and PKM. PKM generation may therefore trigger one or more additional pathways contributing to tau phosphorylation following inappropriate calcium influx.
Ekinci
F J
FJ
Department of Biological Sciences, University of Massachusetts-Lowell 01854, USA.
Shea
T B
TB
D001345:Autoradiography; D000001:Calcimycin / Q000494:pharmacology; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D002154:Calpain / Q000494:pharmacology; D002384:Catalysis; D051360:Cyclin-Dependent Kinase 5; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D003720:Densitometry; D020536:Enzyme Activators / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D015151:Immunoblotting; D007150:Immunohistochemistry; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D010446:Peptide Fragments / Q000378:metabolism; D010766:Phosphorylation; D011493:Protein Kinase C / Q000378:metabolism*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D016875:tau Proteins / Q000378:metabolism*
D020536:Enzyme Activators; D004791:Enzyme Inhibitors; D010446:Peptide Fragments; D016875:tau Proteins; D000001:Calcimycin; D051360:Cyclin-Dependent Kinase 5; D011493:Protein Kinase C; D017871:Calcium-Calmodulin-Dependent Protein Kinases; C495905:CDK5 protein, human; D018844:Cyclin-Dependent Kinases; D020928:Mitogen-Activated Protein Kinases; D002154:Calpain; D013755:Tetradecanoylphorbol Acetate